Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 31Lung Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Ovarian Neoplasms 5Esophageal Neoplasms 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Retinoblastoma 2Neoplasms 2Neoplasm Metastasis 2Head and Neck Neoplasms 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous-Cell Lung Cancer 1Sjogren's Syndrome 1Scleroderma, Systemic 1Retinal Neoplasms 1Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC) 1Resectable Non-small Cell Lung Cancer 1Resectable Lung Non-Small Cell Carcinoma 1Recurrence 1Psoriasis 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Cancer Recurrent 1Oropharyngeal Neoplasms 1Nonsquamous Non-small Cell Lung Cancer 1Non-Squamous Non-Small Cell Lung Cancer 1NSCLC 1Multiple Sclerosis 1Melanoma 1

Interventions

pembrolizumab 1patritumab deruxtecan 1Platinum Compounds 1Pemetrexed 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Nonsquamous Non-small Cell Lung Cancer × Platinum Compounds × Clear all
NCT05338970 2025-01-31

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Daiichi Sankyo

Phase 3 Active not recruiting
586 enrolled
Thoracic

Nonsquamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡